A tumor-specific catalytic nanomedical drug Fe-MOF@GOD/anti-VEGFR2 (abbreviated as MGaV) was prepared by Zhou et al. using Fe-BTC loaded with glucose oxidase (GOD) through coupling and combined with anti-VEGFR2. This evidence concerns the gene KDR and neoplasm.